Understanding Cholesterol Guidelines and Implementing Non-statins in High-Risk Populations: Paired Conversations and Case Vignettes

To participate in this activity, please:

An interprofessional faculty of primary care and specialty clinicians discuss real-world issues in managing patients with complex and challenging dyslipidemia, including elevated lipoprotein a (Lp(a)). Several paired conversations serve as the foundation for discussions related to recent cholesterol guidelines, patient risk stratification, and recommended goals for patients at risk of atherosclerotic cardiovascular disease. Two case vignettes provide the basis for robust discussion among the faculty, which centers around clinical decision-making and the roles, benefits, and limitations of approved and investigational pharmacologic treatment options. The 1.5-hour program format fosters critical thinking and application of key concepts to patient cases, enabling participants to advance their clinical practice.

The conversations are also available as a podcast: You may listen here

Course Credit:

1.5 ACPE Contact Hours
1.5 AMA PRA Category 1 CreditsTM
1.5 ANCC Contact Hours
1.5 CA-BRN Contact Hours


Opens: 2023-12-29
Closes: 2024-12-29

Target Audience:

This activity was developed for cardiologists, lipidologists, internal medicine specialists, primary care physicians, nurse practitioners, physician associates/assistants, pharmacists and other clinicians who have a role in the diagnosis, treatment, and monitoring of patients with hyperlipidemia.

This activity is supported by an independent educational grant from Novartis Pharmaceuticals.


In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1.5 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 ANCC contact hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Additional Content Planners

James Backes, PharmD (Medical Writer)
No significant relationships to disclose.

Jada Dillner, PA (Peer Reviewer)
No significant relationships to disclose.

Heather Jimenez, MSN, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • John E. Anderson, MD

    Internal Medicine and Diabetes
    The Frist Clinic
    Nashville, Tennessee

  • James M. Backes, PharmD

    Associate Dean for Clinical and Medical Center Affairs
    Assistant Director Atherosclerosis and LDL-Apheresis Center
    School of Pharmacy
    Kansas City, Kansas

  • Deepak L. Bhatt, MD, MPH

    Director, Mount Sinai Heart and the Cardiovascular Institute
    Dr. Valentin Fuster Professor of Cardiovascular Medicine
    Icahn School of Medicine
    Mount Sinai Health System
    New York, New York

  • Seth S. Martin, MD

    Director of the Advanced Lipid Disorders Program and Digital Health Lab
    Ciccarone Center for the Prevention of Cardiovascular Disease
    Associate Professor of Medicine
    Johns Hopkins
    Baltimore, Maryland

  • Colleen Walsh-Irwin, DNP

    Associate Director
    Evidence-Based Practice at Department of Veterans Affairs
    E. Northport, New York

Learning Objectives

  • Understanding of Lp(a) recommendations and management according to recent cholesterol guidelines
  • Implement nonstatin therapy among those not achieving lipid treatment targets with or not tolerating statin therapy
  • Utilize validated risk assessment tools to classify individual patients
  • Recognize lipid targets and thresholds for initiating nonstatin therapy
  • Implement strategies to limit common barriers for initiating nonstatin therapies
  • Utilize practice cases for understanding guideline recommendations for initiating new therapies

Faculty Disclosures

John E. Anderson, MD

Advisory Board: Abbott Diabetes
Consultant: Bayer, Biolink, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi
Speakers Bureau: Bayer, Eli Lilly, Novo Nordisk, Sanofi

James M. Backes, PharmD

No relationships to disclose.

Deepak L. Bhatt, MD, MPH

Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Janssen, McKinsey, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys
Consultant: GlaxoSmithKline, Hims, SFJ, Youngene
Data Monitoring Committees: Acesion Pharma, Boston Scientific, Contego Medical, Novartis
Honoraria: CSL Behring (AHA lecture), Cowen and Company, Piper Sandler
Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio
Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Unfunded Research: FlowCo.

Seth S. Martin, MD

Advisory Board: Amgen, AstraZeneca, BMS, Merck, NewAmsterdam
Consultant: Premier

Colleen Walsh-Irwin, DNP

No relationships to disclose.